Skip to content
Screener
Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
Revenue by Product
Revenue Under Collaboration Agreements$57K-97.8%$2.49M+1,085%$6.86M-91.4%$55K-96.3%$2.59M+419%
Revenue Under Supply Agreements$7.39M+2,188%$2.74M$901K+147%$1.15M$323K
Revenue by Geography
DK$2.99M+3.7%$2.78M+1,222%$2.88M
JP$3.37M
Non Us$4.08M+11,909%$2.45M$34K-99.8%
US$26.21M+105%$17.45M+125%$12.8M+606%

FAQ

How does ARS Pharmaceuticals, Inc. break its business down?
ARS Pharmaceuticals, Inc. (SPRY) reports revenue by product across 2 parts — Revenue Under Collaboration Agreements and Revenue Under Supply Agreements. Each is extracted from the segment footnotes and tracked over time.
Where does ARS Pharmaceuticals, Inc.'s segment data come from?
Segment breakdowns are pulled from the segment footnotes in ARS Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.